Imugene to demonstrate the benefits of combination tumor treatment
Finfeed Archived Oct 21, 2019
Imugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology.
GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer
Next Investors Archived Oct 02, 2019
Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).
Rhythm’s lead biomarker successfully differentiates between cancer and healthy samples
Finfeed Archived Sep 19, 2019
New antibodies for the key lead biomarker used in Rhythm Biosciences' (ASX: RHY) ColoSTAT® test can successfully differentiate between cancer and healthy samples, and the test has now been optimised.
One ASX Med-Tech is Set to Transform The $100+Billion Cancer Diagnostic Market
Next Investors Archived Aug 14, 2019
MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.
Genetic Technologies poised to unveil market moving news
Finfeed Archived May 07, 2019
Genetic Technologies Ltd (ASX:GTG) has established a Memorandum of Understanding with TGen, an Arizona-based biomedical research institute dedicated to conducting ground-breaking research with life changing results.